::Affinity Photoprobes, LLC::

Affinity Photoprobes,™ built it's foundation on patented technology called nucleotide photoaffinity labeling. This technology is a photochemical process that enables specific attachment of a radioactive nucleotide to specific enzymes at their active sites. As nucleotide binding proteins vary in diseased verses normal or healthy tissues, nucleotide photoaffinity labeling technology allows for the identification of various enzyme and protein differences between normal and diseased tissues such as Alzheimer's and Lou Gehrig' Disease (ALS). The development of the technology was supported by continuing NIH grants for over 25 years and has become an integral research tool for nearly 300 academic research institutions, biotech and pharmaceutical companies worldwide.

Many research applications have been identified and published using Nucleotide Photoaffinity Labeling such as enzymological studies for active catalytic site identification and the detection of aberrant nucleotide binding proteins in diverse tissues in cancer, Alzheimer's, and bacterial infections. Nucleotide Photoaffinity Labeling is also used for clinical testing of the effects of toxic compounds on tissues and for the rapid production of radiolabeled antibodies and super-antibodies which retain most or all of their antigen recognition ability. These radiolabeled antibodies are being used in radio-immunoassays verses radio-iodinated antibodies, comparatively. Compounds are also available that allow for rapid simple introduction of biotin into any primary antibody for conventional biotin-avidin based immunology.